ORGS vs. LUMO, TCRT, MEIP, SYBX, BIVI, NRBO, BNTC, KALA, CPIX, and COCP
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Lumos Pharma (LUMO), Alaunos Therapeutics (TCRT), MEI Pharma (MEIP), Synlogic (SYBX), BioVie (BIVI), NeuroBo Pharmaceuticals (NRBO), Benitec Biopharma (BNTC), KALA BIO (KALA), Cumberland Pharmaceuticals (CPIX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical preparations" industry.
Lumos Pharma (NASDAQ:LUMO) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
In the previous week, Lumos Pharma had 6 more articles in the media than Orgenesis. MarketBeat recorded 6 mentions for Lumos Pharma and 0 mentions for Orgenesis. Lumos Pharma's average media sentiment score of 0.00 beat Orgenesis' score of -0.16 indicating that Orgenesis is being referred to more favorably in the news media.
Lumos Pharma received 33 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
34.0% of Lumos Pharma shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by insiders. Comparatively, 5.7% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Orgenesis has a net margin of -1,010.50% compared to Orgenesis' net margin of -2,434.69%. Orgenesis' return on equity of -119.87% beat Lumos Pharma's return on equity.
Lumos Pharma currently has a consensus target price of $18.00, suggesting a potential upside of 608.66%. Given Orgenesis' higher probable upside, analysts plainly believe Lumos Pharma is more favorable than Orgenesis.
Lumos Pharma has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
Lumos Pharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Summary
Lumos Pharma beats Orgenesis on 11 of the 17 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
